You are here:

vernakalant (Brinavess)

Advice

in the absence of a submission from the holder of the marketing authorisation:

vernakalant (Brinavess®) is not recommended for use within NHS Scotland.

Indication under review: Rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults
• For non-surgery patients: atrial fibrillation ≤ 7 days duration
• For post-cardiac surgery patients: atrial fibrillation ≤ 3 days duration

The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication.  As a result we cannot recommend its use within NHSScotland.

Drug Details

Drug Name: vernakalant (Brinavess)
SMC Drug ID: 1222/17
Manufacturer: Cardiome UK Limited
Indication: rapid conversion of recent onset atrial fibrillation to sinus rhythm in adults For non-surgery patients: atrial fibrillation ≤ 7 days duration For post-cardiac surgery patients: atrial fibrillation ≤ 3 days duration
BNF Category:
Sub Category: 2.3 Anti-arrhythmic drugs
Submission Type: Non submission
Status: Not Recommended
Date Advice Published: 13 February 2017

Back